Market Overview

Wednesday's Market Movers (IDIX, JBL, AMAT)

Related IDIX
What Investors Are Watching For In Regulus Therapeutics' Next Data Release
Wall Street's Hall Of Fame (And Hall Of Shame): The Best And Worst Analyst Recommendations Of 2014

Idenix Pharmaceuticals (NASDAQ: IDIX): Idenix Pharmaceuticals traded up over 16% early on Wednesday after it announced positive clinical data for HVC drug candidates.

Ron Renaud, President and Chief Executive Officer of Idenix, stated, "We are encouraged by the initial SVR results from the phase IIb program, which have confirmed previous data showing that IDX184 is a potent nucleotide inhibitor with a profile supporting its potential role as a key component of all-oral direct-acting antiviral (DAA) combination regimens for HCV."

Jabil Circuit (NYSE: JBL): Jabil Circuit, an electronic service and solution provider, traded up over 6% on Wednesday after the company released third quarter results. Jabil's earnings per share were $0.64 per diluted share, compared to the third quarter in 2011, which was $0.58 per diluted share.

Timothy L. Main, President and CEO of Jabil, commented, "We are pleased to post core EBITDA margins of 6.5 percent in the quarter, our highest level since 2005. Core operating margins also expanded to 4.5 percent."

Main further stated, "This is particularly gratifying during a period of more subdued revenue growth for the company overall."

Applied Materials (NASDAQ: AMAT): Applied Materials traded up about 3% early on Wednesday. The company was upgraded to Overweight at Barclays.

Latest Ratings for IDIX

Jun 2014UBSDowngradesBuyNeutral
Jun 2014BairdUpgradesUnderperformNeutral
Jan 2014JMP SecuritiesDowngradesMarket PerformMarket Underperform

View More Analyst Ratings for IDIX
View the Latest Analyst Ratings

Posted-In: Earnings Long Ideas News Short Ideas Upgrades FDA Intraday Update Analyst Ratings Best of Benzinga


Related Articles (AMAT + IDIX)

View Comments and Join the Discussion!

Partner Center